Shares of Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) saw an uptick in trading volume on Monday . 1,129,714 shares were traded during trading, an increase of 1,728% from the previous session’s volume of 61,805 shares.The stock last traded at $3.78 and had previously closed at $3.90.
Raia Drogasil Stock Down 2.1%
The company’s 50 day simple moving average is $3.57 and its 200-day simple moving average is $4.22.
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05. The firm had revenue of $2.17 billion for the quarter, compared to analysts’ expectations of $2.32 billion. As a group, equities analysts anticipate that Raia Drogasil S.A. will post 0.16 earnings per share for the current fiscal year.
About Raia Drogasil
Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.
The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.
See Also
- Five stocks we like better than Raia Drogasil
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
